Literature DB >> 32435379

Combined Peptide and Small-Molecule Approach toward Nonacidic THIQ Inhibitors of the KEAP1/NRF2 Interaction.

Jesus M Ontoria1, Ilaria Biancofiore1, Paola Fezzardi1, Federica Ferrigno1, Esther Torrente1, Stefania Colarusso1, Elisabetta Bianchi1, Matteo Andreini1, Alexandros Patsilinakos1, Georg Kempf2, Martin Augustin2, Stefan Steinbacher2, Vincenzo Summa1, Robert Pacifici3, Ignacio Muñoz-Sanjuan3, Larry Park3, Alberto Bresciani1, Celia Dominguez3, Leticia Toledo Sherman3, Steven Harper1.   

Abstract

The NRF2-ARE pathway is an intrinsic mechanism of defense against oxidative stress. Inhibition of the interaction between NRF2 and its main negative regulator KEAP1 is an attractive strategy toward neuroprotective agents. We report here the identification of nonacidic tetrahydroisoquinolines (THIQs) that inhibit the KEAP1/NRF2 protein-protein interaction. Peptide SAR at one residue is utilized as a tool to probe structural changes within a specific pocket of the KEAP1 binding site. We used structural information from peptide screening at the P2 pocket, noncovalent small-molecules inhibitors, and the outcome from an explorative SAR at position 5 of THIQs to identify a series of neutral THIQ analogs that bind to KEAP1 in the low micromolar range. These analogs establish new H-bond interactions at the P3 and P2 pockets allowing the replacement of the carboxylic acid functionality by a neutral primary carboxamide. X-ray crystallographic studies reveal the novel binding mode of these molecules to KEAP1.
Copyright © 2020 American Chemical Society.

Entities:  

Year:  2020        PMID: 32435379      PMCID: PMC7236277          DOI: 10.1021/acsmedchemlett.9b00594

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  15 in total

1.  Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response.

Authors:  Kit I Tong; Balasundaram Padmanabhan; Akira Kobayashi; Chengwei Shang; Yosuke Hirotsu; Shigeyuki Yokoyama; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

Review 2.  Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).

Authors:  Alberto Bresciani; Antonino Missineo; Mariana Gallo; Mauro Cerretani; Paola Fezzardi; Licia Tomei; Daniel Oscar Cicero; Sergio Altamura; Alessia Santoprete; Raffaele Ingenito; Elisabetta Bianchi; Robert Pacifici; Celia Dominguez; Ignacio Munoz-Sanjuan; Steven Harper; Leticia Toledo-Sherman; Larry C Park
Journal:  Arch Biochem Biophys       Date:  2017-08-08       Impact factor: 4.013

3.  Binding mode and structure-activity relationships around direct inhibitors of the Nrf2-Keap1 complex.

Authors:  Eric Jnoff; Claudia Albrecht; John J Barker; Oliver Barker; Edward Beaumont; Steven Bromidge; Frederick Brookfield; Mark Brooks; Christian Bubert; Tom Ceska; Vincent Corden; Graham Dawson; Stephanie Duclos; Tara Fryatt; Christophe Genicot; Emilie Jigorel; Jason Kwong; Rosemary Maghames; Innocent Mushi; Richard Pike; Zara A Sands; Myron A Smith; Christopher C Stimson; Jean-Philippe Courade
Journal:  ChemMedChem       Date:  2014-02-06       Impact factor: 3.466

4.  Discovery of potent Keap1-Nrf2 protein-protein interaction inhibitor based on molecular binding determinants analysis.

Authors:  Zheng-Yu Jiang; Meng-Chen Lu; Li Li Xu; Ting-Ting Yang; Mei-Yang Xi; Xiao-Li Xu; Xiao-Ke Guo; Xiao-Jin Zhang; Qi-Dong You; Hao-Peng Sun
Journal:  J Med Chem       Date:  2014-02-21       Impact factor: 7.446

5.  Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.

Authors:  Jakob S Pallesen; Kim T Tran; Anders Bach
Journal:  J Med Chem       Date:  2018-05-29       Impact factor: 7.446

Review 6.  The Keap1-Nrf2-ARE Pathway As a Potential Preventive and Therapeutic Target: An Update.

Authors:  Meng-Chen Lu; Jian-Ai Ji; Zheng-Yu Jiang; Qi-Dong You
Journal:  Med Res Rev       Date:  2016-05-18       Impact factor: 12.944

Review 7.  Oxidative stress, neurodegeneration, and the balance of protein degradation and protein synthesis.

Authors:  Kalavathi Dasuri; Le Zhang; Jeffrey N Keller
Journal:  Free Radic Biol Med       Date:  2012-09-19       Impact factor: 7.376

8.  Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators.

Authors:  Atul D Jain; Haranatha Potteti; Benjamin G Richardson; Laura Kingsley; Julia P Luciano; Aya F Ryuzoji; Hyun Lee; Aleksej Krunic; Andrew D Mesecar; Sekhar P Reddy; Terry W Moore
Journal:  Eur J Med Chem       Date:  2015-09-04       Impact factor: 6.514

9.  Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles.

Authors:  Ken Itoh; Nobunao Wakabayashi; Yasutake Katoh; Tetsuro Ishii; Tania O'Connor; Masayuki Yamamoto
Journal:  Genes Cells       Date:  2003-04       Impact factor: 1.891

Review 10.  Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes.

Authors:  Marta Pelay-Gimeno; Adrian Glas; Oliver Koch; Tom N Grossmann
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-26       Impact factor: 15.336

View more
  4 in total

1.  LncRNA NEAT1 promotes nucleus pulposus cell matrix degradation through regulating Nrf2/ARE axis.

Authors:  Cheng Li; Xinjian Ma; Chenfei Ni; Jingyan Xu; Yinfei Xie; Junwei Kan; Xiaoli Wei
Journal:  Eur J Med Res       Date:  2021-01-21       Impact factor: 2.175

Review 2.  Cyclobutanes in Small-Molecule Drug Candidates.

Authors:  Marnix R van der Kolk; Mathilde A C H Janssen; Floris P J T Rutjes; Daniel Blanco-Ania
Journal:  ChemMedChem       Date:  2022-03-29       Impact factor: 3.540

3.  Design, synthesis and evaluation of novel small molecules acting as Keap1-Nrf2 protein-protein interaction inhibitors.

Authors:  Yunfeng Sun; Lulu Zheng; Bo Yang; Shuyu Ge; Qiang Li; Mingwan Zhang; Shenghui Shen; Yin Ying
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

Review 4.  NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases.

Authors:  Ángel Cores; Marta Piquero; Mercedes Villacampa; Rafael León; J Carlos Menéndez
Journal:  Biomolecules       Date:  2020-06-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.